GlassScriptPhysician profile
Amber W Rodd
NPI 1497018063
$3,477.07
in general payments reported to CMS, 2019-2025
37 companies · $862 in 2025
The $862 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $716 · 2023: $405 · 2024: $834 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,140.66 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $326.00 | 2021-2025 | Fasenra, Farxiga |
| Pfizer INC. | $198.06 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.79 | 2021-2024 | Spevigo, Ofev |
| Leo Pharma INC. | $153.15 | 2022-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $125.90 | 2021-2025 | Libtayo |
| Novo Nordisk INC | $125.16 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $96.12 | 2021-2023 | |
| Genzyme Corporation | $92.36 | 2023-2025 | |
| Amgen INC. | $89.27 | 2021-2025 | Otezla, Repatha, Tezspire |
| Jazz Pharmaceuticals INC. | $81.63 | 2025 | |
| Verona Pharma, INC. | $70.93 | 2025 | Ohtuvayre |
| Baxter Healthcare | $69.65 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $57.63 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| United Therapeutics Corporation | $57.10 | 2024 | Orenitram, Remodulin |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.70 | 2021-2022 | |
| Philips North America LLC | $53.46 | 2024 | (Ak6) Vest Therapy |
| Astellas Pharma US INC | $45.78 | 2021-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $43.84 | 2022 | |
| Inspire Medical Systems, INC. | $42.26 | 2025 | Inspire |
| Sanofi Pasteur INC. | $38.65 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.61 | 2022 | |
| Insmed, INC. | $33.56 | 2021 | |
| Harmony Biosciences LLC | $31.08 | 2025 | |
| Sumitomo Pharma America, INC. | $22.92 | 2023 | Gemtesa |
| Vifor Pharma, INC. | $22.38 | 2024 | Zemaira |
| Grifols USA, LLC | $20.33 | 2022 | |
| Organogenesis INC. | $19.52 | 2024 | |
| Seqirus USA INC | $18.26 | 2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $17.37 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.66 | 2022 | |
| Abbott Laboratories | $14.39 | 2021 | |
| Inari Medical, INC. | $13.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.68 | 2021 | |
| Inogen, INC. | $8.02 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Rodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.